Brain Tumor Res Treat.  2022 Jul;10(3):158-163. 10.14791/btrt.2022.0018.

Managing Side Effects of Cytotoxic Chemotherapy in Patients With High Grade Gliomas

• Ha H
• Lim JH

• KMID: 2532248
• DOI: http://doi.org/10.14791/btrt.2022.0018

Abstract

Cytotoxic chemotherapy has been a mainstay of cancer treatment since the 1940s. In the recent era of emergent targeted therapies and immunotherapies, many cytotoxic chemotherapy agents including temozolomide are still one of main weapons for the treatment of high grade gliomas. However, cytotoxic chemotherapy often causes side effects. Proper management of chemotherapy-induced toxicity can have a significant impact on a patient’s quality of life and clinical outcomes. Many supportive care advances have transformed our ability to give full doses of chemotherapy, which is important for achieving their full efficacy. Prevention and treatment strategies have been developed for many chemotherapy-related toxicities. This review focused on managing gastrointestinal toxicity, chemotherapy-induced nausea and vomiting, and hematologic toxicities such as thrombocytopenia during cytotoxic chemotherapy treatment in high-grade brain tumors.

Keyword

Chemotherapy; Brain tumor; Adverse drug event

Reference

1. Sherman JH, Lo SS, Harrod T, Hdeib A, Li Y, Ryken T, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of chemotherapy in the management of adults with newly diagnosed metastatic brain tumors. Neurosurgery. 2019; 84:E175–E177. PMID: 30629221.

2. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22:1073–1113. PMID: 32328653.

3. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016; 374:1344–1355. PMID: 27050206.

4. Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol. 2013; 31:328–336. PMID: 23269986.

5. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013; 31:337–343. PMID: 23071247.

6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987–996. PMID: 15758009.

7. Bae SH, Park MJ, Lee MM, Kim TM, Lee SH, Cho SY, et al. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. J Korean Med Sci. 2014; 29:980–984. PMID: 25045231.

8. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 2005; 6:93–102. PMID: 15683818.

9. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007; 13:181–198. PMID: 18045778.

10. Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist. 2000; 5:250–259. PMID: 10884503.

11. Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014; 15:e447–e460. PMID: 25186048.

12. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27:4733–4740. PMID: 19720927.

13. van Heerden J, Moes N, Balliauw K, Romaen E, Verlooy J, van den Akker M, et al. The management of delayed onset cramps related to irinotecan during oncological treatment. J Cancer Sci Clin Ther. 2021; 5:448–458.

14. Cope DG. Clinical updates in nausea and vomiting. Semin Oncol Nurs. 2022; 38:151249. PMID: 35219568.

15. Aapro M. Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts. Support Care Cancer. 2018; 26(Suppl 1):35–37. PMID: 29556811.

16. National Comprehensive Cancer Network. NCCN guidelines for antiemetics V2.2022. Plymouth Meeting. PA: National Comprehensive Cancer Network;2022.

17. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119–v133. PMID: 27664248.

18. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020; 38:2782–2797. PMID: 32658626.

19. Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019; 27:87–95. PMID: 30284039.

20. Bossaer JB. Olanzapine for chemotherapy-induced nausea and vomiting. N Eng J Med. 2016; 375:1395–1396.

21. Dufner V, Kessler AF, Just L, Hau P, Bumes E, Pels HJ, et al. The emesis trial: depressive glioma patients are more affected by chemotherapy-induced nausea and vomiting. Front Neurol. 2022; 15:13.

22. Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, et al. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer. 2011; 19:697–701. PMID: 20467757.

23. Patel MP, Woodring S, Randazzo DM, Friedman HS, Desjardins A, Healy P, et al. Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Support Care Cancer. 2020; 28:2229–2238. PMID: 31440823.

24. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65:287–291. PMID: 1739631.

25. Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol. 2007; 9:47–52. PMID: 17108062.

26. Arulananda S, Lynam J, Sem Liew M, Wada M, Cher L, Gan HK. Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients. Intern Med J. 2018; 48:1206–1214. PMID: 29923272.

27. Hitchcock IS, Hafer M, Sangkhae V, Tucker JA. The thrombopoietin receptor: revisiting the master regulator of platelet production. Platelets. 2021; 32(suppl 5):770–778. PMID: 34097561.

28. Bolton-Maggs PHB, George JN. Immune thrombocytopenia treatment. N Engl J Med. 2021; 385:948–950. PMID: 34469652.

29. Lozano ML, Rodeghiero F. Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia. Lancet Haematol. 2022; 9:e168–e169. PMID: 35240068.

30. Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, Patwardhan R, Messam C, Mostafa Kamel Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010; 26:2339–2346. PMID: 20735290.

31. Winer ES, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015; 4:16–26. PMID: 25165041.

32. Le Rhun E, Devos P, Houillier C, Cartalat S, Chinot O, Di Stefano AL, et al. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. Neurology. 2019; 93:e1799–e1806. PMID: 31586022.

33. Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014; 22:1217–1222. PMID: 24414994.

34. Li VJ, Miao Y, Wilkins C, Soff GA. Efficacy and thrombotic adverse events of romiplostim use in patients with thrombocytopenia related to underlying malignancies. Blood. 2017; 130(Suppl 1):2324.

35. Al-Samkari H, Kolb-Sielecki J, Safina SZ, Xue X, Jamieson BD. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2022; 9:e179–e189. PMID: 35240074.

36. National Comprehensive Cancer Network. NCCN guidelines for hematopoietic growth factors V1.2022. Plymouth Meeting. PA: National Comprehensive Cancer Network;2022.